23:33:25 Europe / Stockholm

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-08-16 Halvårsrapport
2024-03-28 Årsstämma
2024-02-27 Bokslutskommuniké 2023
2023-08-18 Halvårsrapport
2023-05-05 X-dag ordinarie utdelning NXTMS 0.00 SEK
2023-03-31 Årsstämma
2023-02-27 Bokslutskommuniké 2022
2022-08-12 Halvårsrapport
2022-05-09 X-dag ordinarie utdelning NXTMS 0.00 SEK
2022-03-31 Årsstämma
2022-02-28 Bokslutskommuniké 2021
2021-08-13 Halvårsrapport
2021-05-17 Split NXTMS 100:1
2021-04-30 X-dag ordinarie utdelning NXTMS 0.00 SEK
2021-04-29 Årsstämma
2021-03-01 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-08-14 Halvårsrapport
2020-04-01 X-dag ordinarie utdelning NXTMS 0.00 SEK
2020-02-28 Bokslutskommuniké 2019
2019-11-11 Extra Bolagsstämma 2019
2019-08-16 Halvårsrapport
2019-03-26 X-dag ordinarie utdelning NXTMS 0.00 SEK
2019-03-25 Årsstämma
2019-03-04 Bokslutskommuniké 2018
2018-11-26 Split NXTMS 30:1
2018-11-21 Extra Bolagsstämma 2018
2018-08-16 Halvårsrapport
2018-03-29 X-dag ordinarie utdelning NXTMS 0.00 SEK
2018-03-28 Årsstämma
2018-02-28 Bokslutskommuniké 2017
2017-08-16 Halvårsrapport
2017-03-29 X-dag ordinarie utdelning NXTMS 0.00 SEK
2017-03-28 Årsstämma
2017-02-28 Bokslutskommuniké 2016
2017-02-17 Extra Bolagsstämma 2017
2016-08-17 Halvårsrapport
2016-04-01 X-dag ordinarie utdelning NXTMS 0.00 SEK
2016-03-31 Årsstämma
2016-02-29 Bokslutskommuniké 2015
2015-12-22 Extra Bolagsstämma 2015
2015-08-20 Halvårsrapport
2015-04-01 X-dag ordinarie utdelning NXTMS 0.00 SEK
2015-03-31 Årsstämma
2015-02-26 Bokslutskommuniké 2014

Beskrivning

LandFinland
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Nexstim är verksamt inom medicinteknik. Bolaget har utvecklat en icke-invasiv teknik för hjärnstimulering som kallas SmartFocus®. Det är en navigerad magnetisk stimuleringsteknik (nTMS) med 3D-navigering som ger inriktning av TMS till det specifika området av hjärnan. Tekniken är avsedd för behandling av svår depression och kronisk neuropatisk smärta. Bolaget grundades år 2000 och har sitt huvudkontor i Helsingfors.
2023-04-24 12:30:00

Company Announcement, Helsinki, 24 April 2023 at 1:30 PM (EEST)

Nexstim Plc’s New Shares Have Been Registered in Trade Register

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announced on April 18, 2023 that between 1 October 2022 and 31 March 2023, a total of 40,003 Nexstim Plc’s new shares have been subscribed for with the company's stock options 2020A.

These shares subscribed for under the stock options have been registered in the Trade Register on April 24, 2023, as of which date the new shares will establish shareholder rights. After the trade registration the total amount of shares for Nexstim Plc is 6,755,022.

The shares will be traded in the Nasdaq Helsinki Plc’s First North Growth Market Finland marketplace as an additional lot with the company’s old shares starting April 25, 2023.

The terms and conditions of stock option programs with additional information are available on the company's website at https://www.nexstim.com/investors/.

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

The Company’s Certified Advisor is Erik Penser Bank.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com